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abstract
PURPOSE In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five
specialist centers. Many patients are required to travel long distances to access specialist care. The COVID-19
pandemic brought a number of rapid changes into the care for patients with cancer, with increasing utilization of
telemedicine. We aimed to evaluate how the utilization of telemedicine affects professionals and patients across
Scotland and care delivery, at the Beatson West of Scotland Cancer Centre Sarcoma Unit.
METHODS Between June 8 and August 25, 2020, we invited patients and professional sarcoma multidisciplinary
team members to participate in separate online anonymous survey questionnaires, to assess their attitudes
toward telemedicine. Data were extracted, and descriptive statistics were performed.
RESULTS Patient satisfaction (n = 64) with telemedicine was high (mean = 9.4/10) and comparable with
traditional face-to-face appointments (mean = 9.5/10). Patients were receptive to the use of telemedicine in
certain situations, with patients strongly opposed to being told bad news via telemedicine (88%). Providers
recommended the use of telemedicine in certain patient populations and reported largely equivalent workloads
when compared with traditional consultations. Providers reported that telemedicine should be integrated into
regular practice (66%), with patients echoing this indicating a preference for a majority of telemedicine ap-
pointments (57%).
CONCLUSION Telemedicine in sarcoma care is favorable from both clinician and patient perspectives. Utilization
of telemedicine for patients with rare cancers such as sarcomas is an innovative approach to the delivery of care,
especially considering the time and financial pressures on patients who often live a distance away from specialist
centers. Patients and providers are keen to move toward a more flexible, mixed system of care.
JCO Global Oncol 7:1067-1073. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The current COVID-19 global pandemic, caused by the
novel beta-coronavirus Severe Acute Respiratory Syn-
drome coronavirus 2, has spurred on the imple-
mentation of containment measures such as
quarantine, self-isolation, and physical distancing
across the country, including in healthcare settings, in
an attempt to stem the spread.1,2 Patients with cancer
have been cited as being at higher risk of serious in-
fection, seen in an outbreak at a cancer center in
Edinburgh, Scotland, which resulted in multiple
deaths.3,4 Patients with cancer may not only be more
susceptible to COVID-19, but also incur greater com-
plications as a result of being immunocompromised
because of malignancy or treatment regimes, pulmo-
nary disease, and more frequent exposure to the virus
via the healthcare system.5 To mitigate risks as far as
reasonably possible, it was deemed necessary to re-
structure how care is delivered to patients with cancer.
Guidelines were published by the National Institute
for Health and Care Excellence (NICE) in March
2020, which outlined recommendations for the de-
livery of cancer care in the United Kingdom during
the COVID-19 pandemic.6 These included the post-
poning of nonessential procedures, prioritizing pa-
tients for systemic treatment, and conversion of face-
to-face (FTF) appointments to telemedicine where
appropriate. Where FTF appointments were required,
it was advised that patients attend alone. As a result,
this study aims to assess how the changing role of
FTF consultations and the evolution of telemedicine
affect professionals and patients across Scotland
during the pandemic.
Telemedicine as a tool for the delivery of health care to
populations with limited access to care has been in-
creasing in usage since its conception in 1967.7,8
Available literature suggests that telemedicine is
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high levels of satisfaction for both patients and care
providers.9
There is a shortage of literature related to telemedicine in
oncology,10 especially in the management of rare cancers
such as sarcomas. Patients with rare cancers in Scotland
are often required to travel significant distances to access
care at one of the five cancer centers, three of which are
major oncology centers found in Edinburgh, Aberdeen, and
Glasgow. These large distances present both time and fi-
nancial pressures to patients and can present barriers to
care for some patients.
The aim of this study is to add to the increasing body of
literature looking at the changing landscape of cancer care
delivery in the United Kingdom,11 particularly looking at the
use of telemedicine.
METHODS
Patients were given telemedicine appointments with the
consideration of the National Institute of Health and Care
Excellence (NICE) guidelines6 and also relevant internal
policies. The movement of patients from a traditional FTF
appointment to telemedicine was ultimately at the discre-
tion of the treating physician with consideration of the
preferences of the patient. Patients who had progressive
disease widely remained FTF along with those who required
urgent assessment. Telemedical appointments were of-
fered to patients in advance of regularly scheduled
appointments.
Between June 8 and August 25, 2020, patients were invited
to participate in an anonymous online survey questionnaire,
with the option of completing a paper copy (Data Sup-
plement), and professionals from the sarcoma multidisci-
plinary teams (MDTs) were also invited to complete a
separate online survey questionnaire (Data Supplement).
These surveys were modified versions of previously
published surveys11,12 and probed participants for their
views on how their provision of care had been changed by
the evolving role of telemedicine, moving away from FTF
appointments. Data were extracted, and descriptive sta-
tistics were calculated using SPSS. Some questions allowed
the participant to expand on their thoughts, providing
further depth to the analysis.
For the purpose of this study, telemedicine was defined as
being any appointment, which was not undertaken FTF, for
example, a telephone or video consultation.
RESULTS
Patient Survey on Telemedicine
Patient characteristics. A total of 74 patients participated
with a median age of 55 years (range, 19-85 years;
Table 1). All participants indicated their sex as either male
or female in equal sample size (n = 37; Table 1). Patients
were asked to self-identify their ethnicity, with 100%
(n = 74; Table 1) of participants indicating that they were
European or White. The majority of participants were ed-
ucated and had received education at college level or above
(n = 55; 74.3%; Table 1).
Diagnosis and treatment. Most patients were being cared
for by teams based in Glasgow (n = 67; 90.5%; Table 1),
with the remaining participants being cared for by teams
based in Aberdeen (n = 4; 5.4%) and Dundee (n = 2;
2.7%), and one respondent did not indicate. Participating
patients most often finished treatment at the time of sur-
veying (n = 43; 58.1%; Table 1).
Appointments and attitudes toward telemedicine. Patients
were asked whether they had had an appointment re-
garding their care since March 24, 2020 (1 day after the
initiation of lockdown in Scotland). The majority of patients
had received FTF, telephone, or video consultation
CONTEXT
Key Objective
In Scotland, the use of telemedicine in the delivery of cancer care was implemented in a time-pressured environment, in
response to the COVID-19 pandemic. It had not been used at this scale in the care of patients with sarcoma previously in
Scotland. So, the question becomes what are the implications of telemedicine for patients and practitioners in the area of
rare cancers? Therefore, we explore the attitudes of both patients and practitioners toward telemedicine and the impli-
cations for the future care of patients with rare cancers such as sarcomas.
Knowledge Generated
In our sample, patients and practitioners were widely receptive to the use of telemedicine, indicating that it should become part
of regular. Barriers to efficiency were identified, including lack of ability to perform a physical examination and using a
nonvideo call.
Relevance
Our findings can support practitioners to adapt to telemedicine and understand the perspectives of their patients and other
clinical colleagues.
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appointments (n = 74; 99%), with only one participant not
having had an appointment in this time period (1%). Of
those participants who had received an appointment, 54
patients had had one or more telephone appointments with
a member of the sarcoma team (72%), 10 had had one or
more FTF appointments (13%), nine had had an FTF
appointment and then subsequently had telephone ap-
pointments (12%), and one had had another form of
telemedicine appointment such as video consultation
(1%).
Patients who had received FTF appointments reported high
satisfaction with the consultation, with extremely satisfied
being the most commonly reported score (mean = 9.59/
10). Telemedicine appointments had similar satisfaction
scores, with telephone and video appointments having
mean satisfaction scores of 9.43/10 and 9.47/10,
respectively. However, satisfaction scores were more var-
iable with telephone appointment scores ranging from 2-10
of 10 and video from 5-10 of 10. FTF appointment scores
ranged from 8 to 10 of 10. More than half of patients who
had received a telemedicine appointment (by either tele-
phone or video call) had met the person who performed
their consultation previously (n = 32; 55.17%).
When asked going forward how they would like their ap-
pointments to be performed, patients indicated a prefer-
ence to have mostly telemedicine with occasional FTF
appointments (n = 43; 58.1%; Fig 1B). Commonly cited
factors for this decision include reduced time traveling to
hospital (n = 22), reduced cost to travel to hospital (n = 18),
reduced time waiting in hospital (n = 24), and it being more
convenient (n = 32). Patients also indicated the preference
for only telemedicine appointments (n = 11; 14.9%). Pa-
tients who preferred mostly FTF appointments (n = 13;
17.6%) cited that they would find it more reassuring
(n = 13). Patients currently being treated or had completed
treatment in the last 6 months were more likely to indicate a
preference for mostly or entirely FTF appointments (n = 10)
than patients on follow-up treatment. Age, sex, and level of
education in our sample did not affect mode of consultation
preference.
The most commonly reported information that patients
would not like to be told of via telemedicine was bad news
from imagining results (eg, growth of cancer from magnetic
resonance imaging scan or identification of new area of
cancer; n = 57; 89.1%), with 40.6% not wanting to hear
any scan results (n = 26). Patients also indicated that they
would not like to have the results from discussions from
their care team delivered via telemedicine (eg, need for
referral to a surgeon to manage their cancer; n = 36;
56.3%). Few patients would not want to hear results of
blood tests via telemedicine (n = 5; 7.8%; Fig 1A).
Patients reported that they would like to have a specialist
nurse participate in telemedicine consultations on some
occasions, such as when being told bad news (n = 33;
44.6%). Patients showed a preference for being able to
request the attendance of a specialist nurse (n = 33;
44.6%). A large proportion of patients would like to always
have a specialist nurse present (n = 26; 35.1%).
Provider Survey on Telemedicine
Provider characteristics. Most providers who were invited
to participate responded to the provider survey (N = 26).
Most providers were physicians (eight consultant surgeons,
six consultant oncologists, and five registrars [training
oncologists]), with the remaining respondents being nurses
(six clinical nurse specialists and one research nurse); most
had worked on the sarcoma unit for . 5 years (n = 13;
50%) or, 2 years (n = 8; 31%; Table 2). Most were based
in the West of Scotland (n = 12; 46%) with the remaining
being based in the North of Scotland (n = 8; 31%) and the
South East of Scotland (n = 6; 23%).
TABLE 1. Demographic and Clinical Characteristics of Patients Who
Completed the Patient Experience Survey Related to the Use of
Telemedicine (N = 74)








European or White 74 (100)
Others 0 (0)
Education
None or primary school 0 (0)
Secondary school 19 (25.7)
College, diploma, or vocational qualification 31 (41.9)
University or postgraduate degree 24 (32.4)







About to start treatment 1 (1.4)
Currently on treatment 8 (10.8)
Completed treatment , 6months ago and now on FU 12 (16.2)
Completed treatment . 6 months ago and on FU 10 (13.5)
2-5 years post-treatment and on FU 19 (25.7)
. 5 years post-treatment 2 (2.7)
On a tablet for GIST 22 (29.7)
Abbreviations: FU, follow-up; GIST, gastrointestinal stromal tumor.
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Provider attitudes toward telemedicine. The majority of
providers reported that telemedicine appointments took the
same amount of time compared with FTF appointments
(n = 12; 46%). Providers reported that lack of physical
examination in telemedicine appointments sometimes
negatively affected their ability to provide care (n = 12;
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FIG 1. Summary of key patient and provider survey findings. (A) Information that patients would not want to hear via telemedicine. (B) Patient preferences for
futuremodes of consultation. (C) Clinician-reported workload associated with telemedicine appointments when compared to similar face to face consultations.
(D) Clinician-reported barriers to efficiency in telemedicine. CT, computed tomography; MRI, magnetic resonance imaging; PC, personal computer; US,
ultrasound.
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46%). Most reported that the use of telemedicine did not
increase their workload (n = 17; 65%), with the majority
indicating that workload was the same as FTF appoint-
ments (n = 11; 42.3%; Fig 1C).
Most commonly reported barriers to efficiency when using
telemedicine were not being able to physically see the
patient if using a nonvideo call (n = 20; 77%), lack of ability
to undertake physical examination (n = 15; 58%), and loss
of rapport (n = 15; 58%; Fig 1D). The majority of providers
indicated that their experience with telemedicine would be
improved by the use of video-enabled telemedicine as
opposed to a telephone call (n = 20; 80%) and better
infrastructure (eg, private office, headset, etc; n = 11; 44%;
Fig 2).
Providers most commonly indicated that telemedicine
should become part of regular practice (n = 17; 66%);
follow-up appointments for patients on surveillance were
indicated as suitable (n = 24; 96%) along with follow-up
appointments for patients on stable doses of oral anticancer
treatments (n = 14; 56%). Only three respondents reported
that telemedicine should not be implemented into practice
postpandemic and patients should always be seen FTF as
before, all of whom were Clinical Nurse Specialists. Most
preferred having time during a specific existing in-person
clinic for telemedicine (n = 17; 65%).
Most clinicians or MDT members did not indicate a pref-
erence for specialist nurses to be present during tele-
medicine consultations (n = 16; 61.5%); Consultant
Oncologists and Registrars are more likely to indicate a
preference for their presence (n = 8; 72.7%). Negative
impacts on education of trainees were of moderate to high
concern with 18 providers scoring a negative impact. 5 of
10 (72%).
DISCUSSION
Telemedicine in the setting of this study was implemented
under nationwide NICE guidance and so did not come
about naturally. Uptake was required in a time-pressured
environment presenting a steep learning curve for both
patients with sarcoma and sarcoma providers. Data
extracted from our research study indicate positive results
regarding patient and provider satisfaction with telemedi-
cine in this setting.
Clinician workload was reported to be largely the same
when using telemedicine when compared with FTF ap-
pointments. Patients reported to have similar satisfaction
with telemedicine appointments when compared with
those who received FTF appointments, although satisfac-
tion with the former was more variable. This should be the
focus of future work to investigate and mitigate the root
TABLE 2. Demographic Characteristics of Providers Who Completed
the Provider Experience Survey Related to the Use of Telemedicine
(N = 26)
Clinician Characteristic No. (%)
Role
Clinical nurse specialist 6 (23.1)
Consultant oncologist 6 (23.1)
Consultant surgeon 8 (30.8)
Registrar 5 (19.2)
Research nurse 1 (3.8)
Geographical base
North of Scotland 8 (30.8)
South East of Scotland 6 (23.1)
West of Scotland 12 (46.2)
Time worked, years
, 2 8 (30.8)
2-5 5 (19.2)
. 5 13 (50.0)
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FIG 2. Patient preferences for occa-
sions to have a specialist nurse present
during telemedicine consultations.
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causes of dissatisfaction in patients related to telemedicine
consultations.
There was a general consensus with providers that tele-
medicine should play a role in the delivery of care to pa-
tients with sarcoma postpandemic for certain populations,
in particular, follow-up surveillance appointments and for
those who were on stable doses of oral anticancer medi-
cations. Findings by Smrke et al (2020) were congruent,
with 89% of clinicians in their sample indicating these
populations as appropriate for telemedicine. Patients
echoed this feeling, preferring to have predominantly
telemedicine appointments with occasional FTF appoint-
ments. Patients were receptive to receiving telemedicine
consultations, given that they were reassured that a
physical examination was not needed. This indicates that
going forward, telemedicine should be used for certain
patient populations.
Perhaps unsurprisingly, the majority of patients were op-
posed to receiving bad news from imaging results via
telemedicine. It is a common phenomenon that patients are
opposed to hearing bad news via telemedicine.10,13 This is
in contrast to another study of patients with sarcoma during
the pandemic, in which a large proportion of patients were
not opposed to hearing bad news via telemedicine.11 This
discrepancy requires exploration in future studies.
Providers indicated that telemedicine should be integrated
into routine provision of care in patients with sarcoma,
citing that video-enabled telemedicine was an important
improvement, which should be made along with im-
provements in infrastructure. The Scottish National Health
Service during the pandemic has made concerted efforts to
improve their information technology infrastructure14 with
the adoption of video-enabled call platforms such as Near
Me and Microsoft Teams.
Certain providers felt that the presence of a specialist nurse
during the clinical encounter would be an important
addition, with patients echoing this sentiment. We should
emphasize the importance of stakeholder confidence in the
use of telemedicine; the care of patients with sarcoma in
Scotland involves not only multiple stakeholders across
systems including but not limited to the MDT teams
in hospital settings, but also pharmacy workers and care
staff externally, as noted by Smrke et al.11 In particular,
pharmacy teams are essential in the provision of treatments
for patients with gastrointestinal stromal tumors who
had supplies sent to their home addresses during the
pandemic.
Future work should be carried out to assess the impact of
telemedicine on patient outcomes as we move into a new
care delivery model. Our sample lacked representation
from ethnic minorities and so future work should be
complete to include this population, in particular, the role of
the interpreter should be explored.
In conclusion, this study provides valuable insights into the
benefits of telemedicine in the provision of care for patients
with rare cancers. Although the mode of implementation
was required given a global health emergency, there has
been increasing interest over the past couple of decades on
how the use of telemedicine can alleviate pressures on the
health system and increase access to specialist care for
patients with rare cancers. This should be seen as an
opportunity to redesign the provision of cancer care in
Scotland for the benefit of the patient, the provider, and the
wider health system.
The experience of both patients and providers was broadly
positive. Patients preferred to have bad news delivered FTF.
Given that providers largely reported similar workloads
associated with telemedicine compared with FTF ap-
pointments and patients had fewer time and cost pres-
sures, it is recommended that this mode of care delivery be
implemented into routine care.
AFFILIATIONS
1Department of Management Science, University of Strathclyde,
Glasgow, United Kingdom
2The Royal Marsden Hospital NHS Foundation Trust, London,
United Kingdom
3Scottish Sarcoma Network, The Beatson West of Scotland Cancer
Centre, Glasgow, United Kingdom
4Scottish Sarcoma Network, Gartnavel General Hospital, Glasgow,
United Kingdom
5Scottish Sarcoma Network, Glasgow Royal Infirmary, Glasgow,
United Kingdom
6Scottish Sarcoma Network, Ninewells Hospital, Dundee,
United Kingdom
7Scottish Sarcoma Network, Aberdeen Royal Infirmary, Aberdeen,
United Kingdom
8Scottish Sarcoma Network, Raigmore Hospital, Inverness,
United Kingdom
9The Institute of Cancer Research, London, United Kingdom
CORRESPONDING AUTHOR
Holly M. McCabe, MSc, University of Strathclyde, Strathclyde Business
School, Glasgow G4 0QU, United Kingdom; e-mail: holly.mccabe@
strath.ac.uk.
SUPPORT
Supported by the Scottish Sarcoma Network.
AUTHOR CONTRIBUTIONS
Conception and design: Alannah Smrke, Fiona Cowie, Jeff White, Peter
Chong, Steven Lo, Walter Mmekka, Robin L. Jones, Ioanna Nixon
Administrative support: Holly M. McCabe, Walter Mmekka, Lorraine
Stirling, Lindsay Campbell
Provision of study materials or patients: Alannah Smrke, Fiona Cowie, Jeff
White, Steven Lo, Michelle Ferguson, Walter Mmekka
Collection and assembly of data: Holly M. McCabe, Fiona Cowie, Jeff
White, Ashish Mahendra, Sanjay Gupta, Michelle Ferguson, David
McCabe et al
1072 © 2021 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 94.174.119.81 on August 3, 2021 from 094.174.119.081
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
Boddie, Walter Mmekka, Lindsay Campbell, Robin L. Jones, Ioanna
Nixon
Data analysis and interpretation: Holly M. McCabe, Alannah Smrke, Peter
Chong, Ashish Mahendra, Sanjay Gupta, Walter Mmekka, Lorraine
Stirling, Ioanna Nixon
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
The following represents disclosure information provided by the authors
of this manuscript. All relationships are considered compensated unless
otherwise noted. Relationships are self-held unless noted. I = Immediate
Family Member, Inst = My Institution. Relationships may not relate to the
subject matter of this manuscript. For more information about ASCO’s
conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.
org/go/authors/author-center.
Open Payments is a public database containing information reported by
companies about payments made to US-licensed physicians (Open
Payments).
Walter Mmekka
Honoraria: Advanced Accelerator Applications
Consulting or Advisory Role: BMS
Research Funding: BMS UK
Travel, Accommodations, Expenses: Pierre Fabre
Robin L. Jones
Consulting or Advisory Role: Lilly, Immune Design, Merck Serono,
Adaptimmune, Daiichi Sankyo, Eisai, Morphotek, TRACON Pharma,
Immodulon Therapeutics, Deciphera, PharmaMar, Blueprint Medicines,
Clinigen Group, Epizyme, Boehringer Ingelheim, Bayer, Karma Oncology,
UpToDate
Research Funding: GlaxoSmithKline
Travel, Accommodations, Expenses: PharmaMar
No other potential conflicts of interest were reported.
ACKNOWLEDGMENT
We would like to thank the members of the Scottish Sarcoma Network for
his support for this project, including our nurses and support staff. We
would also like to thank Dr Eugenie Younger for his support.
REFERENCES
1. Prem K, Liu Y, Russell TW, et al: The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: A modelling
study. Lancet Public Health 5:e261-e270, 2020
2. Colbourn T: COVID-19: Extending or relaxing distancing control measures. Lancet Public Health 5:e236-e237, 2020
3. BBC: Covid in Scotland: Deaths in Edinburgh cancer ward after outbreak, 2020. https://www.bbc.co.uk/news/uk-scotland-edinburgh-east-fife-54485272
4. Saini KS, Tagliamento M, Lambertini M, et al: Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52
studies. Eur J Cancer 139:43-50, 2020
5. Robilotti EV, Babady NE, Mead PA, et al: Determinants of COVID-19 disease severity in patients with cancer. Nat Med 26:1218-1223, 2020
6. National Institute for Health and Care Excellence: COVID-19 Rapid Guideline: Delivery of Systemic Anti-Cancer Treatments. London, United Kingdom, National
Institute for Health and Care Excellence, 2020
7. Heinzelmann PJ, Lugn NE, Kvedar JC: Telemedicine in the future. J Telemed Telecare 11:384-390, 2005
8. Herendeen N, Deshpande P: Telemedicine and the patient-centered medical home. Pediatr Ann 43:e28-e32, 2014
9. Hailey D, Roine R, Ohinmaa A: Systematic review of evidence for the benefits of telemedicine. J Telemed Telecare 8:1-7, 2002
10. Doolittle GC, Allen A: Practising oncology via telemedicine. J Telemed Telecare 3:63-70, 1997
11. Smrke A, Younger E, Wilson R, et al: Telemedicine during the COVID-19 pandemic: Impact on care for rare cancers. JCO Glob Oncol 6:1046-1051, 2020
12. Younger E, Smrke A, Lidington E, et al: Health-related quality of life and experiences of sarcoma patients during the COVID-19 pandemic. Cancers (Basel)
12:2288, 2020
13. Wolf I, Waissengrin B, Pelles S: Breaking bad news via telemedicine: A new challenge at times of an epidemic. Oncologist 25:e879, 2020
14. Hutchings R: The Impact of Covid-19 on the Use of Digital Technology in the NHS. Nuffield Trust, 2020. https://www.nuffieldtrust.org.uk/research/the-impact-
of-covid-19-on-the-use-of-digital-technology-in-the-nhs
n n n
Impact of Telemedicine on Sarcoma Care in Scotland
JCO Global Oncology 1073
Downloaded from ascopubs.org by 94.174.119.81 on August 3, 2021 from 094.174.119.081
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
